Page last updated: 2024-11-06

fructose-6-phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fructose-6-phosphate (F6P) is a key intermediate in both glycolysis and gluconeogenesis. It is synthesized from glucose-6-phosphate by the enzyme phosphoglucose isomerase. F6P is a substrate for phosphofructokinase-1 (PFK-1), the rate-limiting enzyme of glycolysis, which converts it to fructose-1,6-bisphosphate. It is also a substrate for the enzyme fructose-6-phosphate 2-kinase/fructose-2,6-bisphosphatase, which regulates the activity of PFK-1. F6P plays a crucial role in carbohydrate metabolism and is involved in the regulation of blood glucose levels. It is also important for the biosynthesis of amino acids, nucleotides, and other essential molecules. F6P is studied extensively to understand the complex metabolic pathways involved in energy production and regulation of cellular processes. Research on F6P helps to elucidate the mechanisms of metabolic disorders such as diabetes and cancer.'

fructose-6-phosphate: RN given refers to parent cpd with unspecified isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fructose 6-phosphate : A ketohexose monophosphate consisting of fructose having a phosphate group located at the 6-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID69507
CHEBI ID15946
SCHEMBL ID8230
MeSH IDM0089611

Synonyms (34)

Synonym
6814-87-5
CHEBI:15946
d-fructose 6-(dihydrogen phosphate)
[2,3,4-trihydroxy-2-(hydroxymethyl)tetrahydrofuran-5-yl] methoxyphosphonic acid
d-fructose, 6-(dihydrogen phosphate) (9ci)
fructose 6-(dihydrogen phosphate)
fructose, 6-(dihydrogen phosphate), d- (8ci)
fructose-6-phosphate
fructose-6-p
643-13-0
FRUCTOSE-6P ,
fru-6-p
d-fructose-6-p
d-fructose-6-phosphate
DB04493
A11865AF-7AEE-49E2-AC87-1C29398404B3
[(2r,3r,4s)-2,3,4,6-tetrahydroxy-5-oxohexyl] dihydrogen phosphate
fructose 6-phosphate
2012qm764y ,
unii-2012qm764y
einecs 211-395-6
fructose, 6-(dihydrogen phosphate)
fructose, 6-(dihydrogen phosphate), d-
fructose-6-phosphate [mi]
SCHEMBL8230
GSXOAOHZAIYLCY-HSUXUTPPSA-N
d-fructose-6p
{[(2r,3r,4s)-2,3,4,6-tetrahydroxy-5-oxohexyl]oxy}phosphonic acid
d-fructose 6-phosphorate
6-o-phosphono-d-fructose
DTXSID80904350
Q32039197
HY-113407
CS-0059357

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" It is also shown that increased gene dosage can exert its influence not merely by enhancing the amounts of gene products but also by altering their biochemical nature."( Gene dosage and Down's syndrome: metabolic and enzymatic changes in PC12 cells overexpressing transfected human liver-type phosphofructokinase.
Ben-Hur, H; Bernstein, Y; Degani, H; Elson, A; Groner, Y; Levanon, D, 1992
)
0.28
" In addition, we describe acute effect of CS-917 on fasting hyperglycemia in overnight-fasted GK rats and chronic effect of CS-917 in multiple dosing GK rats."( CS-917, a fructose 1,6-bisphosphatase inhibitor, improves postprandial hyperglycemia after meal loading in non-obese type 2 diabetic Goto-Kakizaki rats.
Fujiwara, T; Hagisawa, Y; Izumi, M; Ohsumi, J; Okuno, A; Takahashi, K; Yoshida, T, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
D-fructose 6-phosphateA ketohexose monophosphate that is D-fructose having a phosphate substituent at position 6. It is an important intermediate in the carbohydrate metabolism.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (62)

PathwayProteinsCompounds
Glutamate Metabolism2244
Glycolysis1423
Gluconeogenesis2232
Amino Sugar Metabolism1731
Fructose and Mannose Degradation1830
Pentose Phosphate Pathway1527
4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency2244
Homocarnosinosis2244
Hyperinsulinism-Hyperammonemia Syndrome2244
Sialuria or French Type Sialuria1731
Salla Disease/Infantile Sialic Acid Storage Disease1731
Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke Disease2232
2-Hydroxyglutric Aciduria (D and L Form)2244
Tay-Sachs Disease1731
Glucose-6-phosphate Dehydrogenase Deficiency1527
Ribose-5-phosphate Isomerase Deficiency1527
Transaldolase Deficiency1527
Glycogenosis, Type VII. Tarui Disease1423
G(M2)-Gangliosidosis: Variant B, Tay-Sachs Disease1731
Phosphoenolpyruvate Carboxykinase Deficiency 1 (PEPCK1)2232
Fructosuria1830
Fructose-1,6-diphosphatase Deficiency2232
Triosephosphate Isomerase Deficiency2232
Succinic Semialdehyde Dehydrogenase Deficiency2244
Fanconi-Bickel Syndrome1423
Glycogenosis, Type IB2232
Glycogenosis, Type IC2232
Glycogenosis, Type IA. Von Gierke Disease2232
Warburg Effect4652
Fructose Intolerance, Hereditary1830
Glycolysis and Pyruvate Dehydrogenase2428
Lipopolysaccharide Biosynthesis4153
Glycerol Metabolism3028
Glycerol Metabolism II2930
Glycerol Metabolism III (sn-Glycero-3-Phosphoethanolamine)3030
Glycerol Metabolism IV (Glycerophosphoglycerol)3030
Glycerol Metabolism V (Glycerophosphoserine)3030
Colanic Acid Building Blocks Biosynthesis1723
Lipopolysaccharide Biosynthesis II4053
D-Sorbitol Degradation II56
Lipopolysaccharide Biosynthesis III3352
Glycolysis I1023
Ethanol Fermentation1527
Photosynthesis6324
Calvin-Benson Cycle1321
Chitin Biosynthesis921
Peptidoglycan cytoplasmic synthesis and recycling pathways834
Glucose metabolism in triple-negative breast cancer cells06
Metabolic reprogramming in pancreatic cancer4223
Metabolic pathways of fibroblasts1718
N-glycan biosynthesis010
Carbon assimilation C4 pathway030
SK UDPglcnac19
Relationship between glutathione and NADPH036
Pentose phosphate pathway05
Hexoses metabolism in proximal tubules016
Photosynthetic carbon reduction014
Starch metabolism09
AtMetExpress overview0109
Glycolysis and Gluconeogenesis08
Pentose phosphate metabolism05
Cori cycle121
Biochemical pathways: part I0466

Research

Studies (572)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990147 (25.70)18.7374
1990's151 (26.40)18.2507
2000's145 (25.35)29.6817
2010's110 (19.23)24.3611
2020's19 (3.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 68.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index68.59 (24.57)
Research Supply Index6.38 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index118.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (68.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (0.68%)5.53%
Reviews13 (2.22%)6.00%
Case Studies1 (0.17%)4.05%
Observational1 (0.17%)0.25%
Other567 (96.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]